Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Imaging markers for Alzheimer disease: Which vs how

Open access
Frisoni, Giovanni B., Bocchetta, Martina, Chételat, Gael, Rabinovici, Gil D., de Leon, Mony J., Kaye, Jeffrey, Reiman, Eric M., Scheltens, Philip, Barkhof, Frederik, Black, Sandra E., Brooks, David J., Carrillo, Maria C., Fox, Nick C., Herholz, Karl, Nordberg, Agneta, Jack, Clifford R., Jagust, William J., Johnson, Keith A., Rowe, Christopher C., Sperling, Reisa A., Thies, William, Wahlund, Lars-Olof, Weiner, Michael W., Pasqualetti, Patrizio, DeCarli, Charles, For ISTAART's NeuroImaging Professional Interest Area·2013·Neurology

Abstract

Revised diagnostic criteria for Alzheimer disease (AD) acknowledge a key role of imaging biomarkers for early diagnosis. Diagnostic accuracy depends on which marker (i.e., amyloid imaging, ¹⁸F-fluorodeoxyglucose [FDG]-PET, SPECT, MRI) as well as how it is measured ("metric": visual, manual, semiautomated, or automated segmentation/computation). We evaluated diagnostic accuracy of marker vs metric in separating AD from healthy and prognostic accuracy to predict progression in mild cognitive impairment. The outcome measure was positive (negative) likelihood ratio, LR+ (LR-), defined as the ratio between the probability of positive (negative) test outcome in patients and the probability of positive (negative) test outcome in healthy controls. Diagnostic LR+ of markers was between 4.4 and 9.4 and LR- between 0.25 and 0.08, whereas prognostic LR+ and LR- were between 1.7 and 7.5, and 0.50 and 0.11, respectively. Within metrics, LRs varied up to 100-fold: LR+ from approximately 1 to 100; LR- from approximately 1.00 to 0.01. Markers accounted for 11% and 18% of diagnostic and prognostic variance of LR+ and 16% and 24% of LR-. Across all markers, metrics accounted for an equal or larger amount of variance than markers: 13% and 62% of diagnostic and prognostic variance of LR+, and 29% and 18% of LR-. Within markers, the largest proportion of diagnostic LR+ and LR- variability was within ¹⁸F-FDG-PET and MRI metrics, respectively. Diagnostic and prognostic accuracy of imaging AD biomarkers is at least as dependent on how the biomarker is measured as on the biomarker itself. Standard operating procedures are key to biomarker use in the clinical routine and drug trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e31829d86e8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 225

Metadata

Authors
Frisoni, G. B., Bocchetta, M., Chételat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., Brooks, D. J., Carrillo, M. C., Fox, N. C., Herholz, K., Nordberg, A., Jack, C. R., Jagust, W. J., Johnson, K. A., Rowe, C. C., Sperling, R. A., Thies, W., Wahlund, L.-O., Weiner, M. W., Pasqualetti, P., DeCarli, C., & Area, F. I. N. P. I.
Venue
Neurology
Published
2013-07-30
Volume
81
Issue
5
Pages
487-500
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1965618373
Cited by
225
References
9
FWCI
17.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imaging markers for Alzheimer disease: Which vs how. https://app.cochat.ai/papers/10.1212/wnl.0b013e31829d86e8
The paper
Frisoni, G. B., Bocchetta, M., Chételat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., Brooks, D. J., Carrillo, M. C., Fox, N. C., Herholz, K., Nordberg, A., Jack, C. R., Jagust, W. J., Johnson, K. A., Rowe, C. C., . . . Area, F. I. N. P. I. (2013). Imaging markers for Alzheimer disease: Which vs how. Neurology. https://doi.org/10.1212/wnl.0b013e31829d86e8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.